MEDICINAL FORM OF TNF-α FOR LOCAL ADMINISTRATION
Abstract
Composite preparation of tumor necrosis factor alpha and rheopolyglukin and polyethylene glycol (TNF-α+PG+PEG) was obtained. The specific activity of the samples was 4,13 х 107 IU/mg. The cytolytic activity of drugs TNF-α+PG+PEG and rhTNF-α did not change after 4 months when stored at 6 °С. Preparation TNF-α+PG+PEG provided a moderately prolonged elevation of TNF-alpha in blood of laboratory mice in contrast to TNF-α when they applied to the skin. The composite preparation did not have toxic, allergic and locally irritating action in experiments on laboratory animals.
About the Authors
S. G. Gamaley
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
A. V. Bateneva
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
Z. F. Urmantseva
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
G. M. Sisoyeva
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
Ya. V. Markus
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
E. D. Danilenko
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
V. K. Mikhaylova
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
E. A. Volosnikova
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
G. M. Levagina
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
V. I. Masicheva
Institute of Medical Biotechnology of State Scientific Center of virology and biotechnology “Vektor”
Russian Federation
Russian Federation
References
1. Гамалей С.Г., Батенева А.В., Сысоева Г.М., Даниленко Е.Д. и др. Фармакокинетика и противоопухолевые свойства препарата, содержащего ФНО-α в составе наночастиц // Бюл. экспер. биол. — 2010. — Т. 149, № 3. — С. 296 — 299.
2. Гуторов С.Л., Абрамов М.Е., Черноглазова Е.В. Химиотерапия с предварительным введением Альнорина при диссеминированной меланоме кожи // Профилактика и лечение злокачественных новообразований в современных условиях. — Барнаул, 2007. — С. 102—103.
3. Патент РФ 2067866, МПК A61K35/26, опубл. 20.10.1996.
4. Патент РФ 2144958, МПК C12N 15/28, опубл. 27.01.2000.
5. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. — М., 2005. — 398 с.
6. Gutorov S.L., Slavina E.G., Chertkova A.I., Korotkova O.V. et al. Modulation of melanoma cell sensitivity to the cytotoxicity of antitumor drugs by TNF-α and IFN-α // European Cytokine Network. — 2006. — Suppl., Vol. 17. — P. 94.
7. Laemmli W.H. Cleavage of structural proteins during the assembly of the head of bacterial fage T 4 // Nature. — 1970. — Vol. 227. — P. 680 — 685.
8. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent // J. Biol. Chem. — 1951. — Vol. 193, N 1. — P. 265 — 725.
Review
For citations:
Gamaley S.G., Bateneva A.V., Urmantseva Z.F., Sisoyeva G.M., Markus Ya.V., Danilenko E.D., Mikhaylova V.K., Volosnikova E.A., Levagina G.M., Masicheva V.I. MEDICINAL FORM OF TNF-α FOR LOCAL ADMINISTRATION. Acta Biomedica Scientifica. 2012;(3(2)):264-266. (In Russ.)
Views:
476
Email this article 
